Physician profile
John Mark Redwine
NPI 1548227101
$3,292.31
in general payments reported to CMS, 2019-2025
31 companies · $626 in 2025
The $626 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $422 · 2022: $689 · 2023: $614 · 2024: $942 · 2025: $626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,181.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $717.07 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $371.27 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $326.06 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $276.29 | 2021-2024 | Jardiance |
| Abbvie INC. | $232.89 | 2021-2025 | |
| Pfizer INC. | $200.19 | 2021-2025 | |
| Glaxosmithkline, LLC. | $159.86 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $148.86 | 2021-2024 | |
| Abbott Laboratories | $108.64 | 2022-2024 | Freestyle Libre 3 |
| Astellas Pharma US INC | $104.79 | 2021-2025 | Veozah |
| Shield Therapeutics INC | $83.84 | 2023-2025 | Accrufer |
| Medtronic, INC. | $71.48 | 2024-2025 | Kyphon Express II Kyphopak Tray, Intellis Adaptivestim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.21 | 2021-2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $42.43 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $35.52 | 2023-2025 | Keveyis, Gvoke Hypopen |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $27.91 | 2024 | Zio Monitor, Zio Xt Patch |
| Janssen Pharmaceuticals, INC | $27.78 | 2021 | |
| Dexcom, INC. | $26.61 | 2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $24.78 | 2024 | Korlym |
| Sanofi-Aventis U.S. LLC | $24.73 | 2025 | |
| Horizon Therapeutics Plc | $22.85 | 2023 | Krystexxa |
| Seqirus USA INC | $22.59 | 2025 | Flucelvax |
| Biohaven Pharmaceutical Holding Company LTD. | $22.54 | 2022 | |
| Alnylam Pharmaceuticals INC. | $22.03 | 2024 | Onpattro |
| Idorsia Pharmaceuticals US INC | $21.58 | 2023 | Quviviq |
| Amgen INC. | $21.26 | 2025 | Krystexxa |
| Phathom Pharmaceuticals, INC. | $19.98 | 2024 | Voquezna |
| Exact Sciences Corporation | $17.54 | 2025 | Cologuard Collection Kit |
| Sonex Health, INC. | $17.00 | 2025 | Sx-One Microknife |
| Biohaven Pharmaceuticals, INC. | $14.79 | 2021 | |
| Ethicon US, LLC | $11.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Redwine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.